Showing 4101-4110 of 7016 results for "".
- U.S. Heart Disease Deaths Linked with Substance Use Rose 4% Per Year Between 1999-2019https://reachmd.com/news/us-heart-disease-deaths-linked-with-substance-use-rose-4-per-year-between-1999-2019/2456862/Research Highlights: Despite drops in overall cardiovascular disease deaths from 1999-2019, cardiovascular disease deaths in which substance use was cited as a contributing factor increased an average of 4% per year, with the death rate accelerating to 6.2%
- Immunotherapy Effective on Young Children’s Peanut Allergieshttps://reachmd.com/news/immunotherapy-effective-on-young-childrens-peanut-allergies/2456816/(Photo credit: Getty Images) DALLAS – Nov. 07, 2023 – Low doses of an immunotherapy taken under the tongue safely achieved desensitization to peanut allergies in children ages 1 to 4 years, according to results of a clinical trial conducted b
- Skin-Deep Resilience: Hidden Physical Health Costs for Minority Youth Overcoming Adversityhttps://reachmd.com/news/skin-deep-resilience-hidden-physical-health-costs-for-minority-youth-overcoming-adversity/2456771/When youth thrive despite difficult circumstances, they are usually lauded for their accomplishments. However, overcoming adversity may have a hidden physiological cost, especially for minority youth. A
- Interim Analysis Shows Dupilumab Safe, Effective for AD Treatment at 2 Yearshttps://reachmd.com/news/real-world-effectiveness-of-dupilumab-in-adult-and-adolescent-patients-with-atopic-dermatitis-2-year-interim-data-from-the-prose-registry/2462202/Dupilumab was associated with improved disease control in patients with moderate-to-severe atopic dermatitis (AD) at two years, according to a new interim analysis. The study, published in Dermatology and Therapy, examined two-year data from the PROSE AD Registry (an ongoing, pros
- New Reasons Eating Less Fat Should Be One of Your Resolutionshttps://reachmd.com/news/new-reasons-eating-less-fat-should-be-one-of-your-resolutions/2456770/A UC Riverside study to motivate your new year’s resolutions: it demonstrates that high-fat diets affect genes linked not only to obesity, colon cancer and irritable bowels, but also to the immune system, brain function, and potentially COVID-19 risk. Americ
- YAP and TAZ: Protein Partners Key for Fetal Bone Developmenthttps://reachmd.com/news/yap-and-taz-protein-partners-key-for-fetal-bone-development/2456768/PHILADELPHIA— A pair of proteins, YAP and TAZ, has been identified as conductors of bone development in the womb and could provide insight into genetic diseases such as osteogenesis imperfecta, known commonly as “brittle bone disease.” This small anim
- Op-Ed: Sports Are Fun, Health and Fitness Are Important; Set Your Goals Then Make Them Prioritieshttps://reachmd.com/news/op-ed-sports-are-fun-health-and-fitness-are-important-set-your-goals-then-make-them-priorities/2456719/The winter holiday season is my favorite time of the year. I think many people would agree with me on this statement. However, my reasons for loving this time of year may differ slightly from most. I love the holiday cheer, the time with family, and the kindness that seems to come with
- Early Indicators of Multiple Sclerosis Evident 5 Years Before Diagnosis, Reveals Recent Studyhttps://reachmd.com/news/early-indicators-of-multiple-sclerosis-evident-5-years-before-diagnosis-reveals-recent-study/2456696/A recent study has revealed five early symptoms of multiple sclerosis that can be identified five years prior to the diagnosis. According to Mayo Clinic, “Multiple sclerosis (MS) is a potentially disabling disease of the brain and spinal cord (central nervous system).
- One-Year Safety and Tolerability of Ruxolitinib Cream in Adolescentshttps://reachmd.com/news/one-year-safety-and-tolerability-of-ruxolitinib-cream-in-adolescents/2487407/Key Takeaways Treatment-emergent adverse events were reported in 40.8% of participants over 52 weeks. Low steady-state plasma concentrations were reported during continuous treatment, and the abstract noted no observed treatment-emergent adverse events
- Three-Year Real-World Outcomes With Dupilumab In Severe Asthmahttps://reachmd.com/news/three-year-real-world-outcomes-with-dupilumab-in-severe-asthma/2487282/Key Takeaways At 36 months, 59% of patients continued dupilumab and 41% had discontinued treatment. Among patients who remained on therapy for 36 months, exacerbations and oral corticosteroid use fell while asthma control and lung function improved.